Anjali Gowripalan
banner
agrowlipowli.bsky.social
Anjali Gowripalan
@agrowlipowli.bsky.social
Research Fellow @ ANU, Canberra 🇦🇺 | Viruses and Immunity Group | Interested in creative poxvirus engineering to produce novel therapeutics
Reposted by Anjali Gowripalan
Two vaccine candidates using mRNA technology elicit a potent immune response against HIV

go.nature.com/4mu5q49
mRNA vaccines for HIV trigger strong immune response in people
Nature - Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.
go.nature.com
August 3, 2025 at 12:28 PM
Reposted by Anjali Gowripalan
In @natbiotech.nature.com, CDS-affiliated @itaiyanai.bsky.social and @martinlercher.bsky.social discuss how openness fuels discovery.

They highlight the evolutionary nature of research and advocate for embracing a creative process.

www.nature.com/articles/s41...
Openness guides discovery - Nature Biotechnology
Nature Biotechnology - Openness guides discovery
www.nature.com
June 18, 2025 at 4:05 PM
Reposted by Anjali Gowripalan
🔔Take a look at this article now published at Nature Cancer!

'Tumor antigens preferentially derive from unmutated genomic sequences in #melanoma and non-small cell #lungcancer'

✏️By Pierre Thibault, Claude Perreault & colleagues

🔗 www.nature.com/articles/s43...
Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer - Nature Cancer
Based on a proteogenomic analysis, Perreault and colleagues report that the majority of predicted tumor antigens originate from unmutated genomic sequences in melanoma and non-small cell lung cancer.
www.nature.com
June 4, 2025 at 9:58 AM
Reposted by Anjali Gowripalan
A great story showcasing the brilliant Yi Ning Fu, who I had the privilege of supervising last year as a student with the equally fantastic @agrowlipowli.bsky.social. It's a huge pleasure scienceing with them.
May 2, 2025 at 2:01 PM
Reposted by Anjali Gowripalan
New research suggests that there is no reputational penalty for shared first authorships, even for the person named second

https://go.nature.com/4l3qtdS
Does sharing first authorship on a paper carry a penalty? What the research says
Study dispels myth that order of names in a paper’s author list dictates perception of success.
go.nature.com
March 25, 2025 at 10:57 AM
Reposted by Anjali Gowripalan
📸 Join Nature’s photo competition for a chance to be featured in the magazine, win a print and online subscription to the journal, and take home £500

Submit your best #ScientistAtWork photo to photocompetition@nature.com. Entries close on Friday!
March 25, 2025 at 6:01 PM
The first rule of virus making:

All you need is one,

but two is better.
February 10, 2025 at 2:31 AM
Super cool example of viral trickery for oncolytic therapy
nature.com Nature @nature.com · Jan 17
Scientists have disguised tumours to ‘look’ similar to pig organs ― tricking the immune system into attacking the cancerous cells.

www.nature.com/articles/d41...
How to trick the immune system into attacking tumours
Lab-grown viruses make cancer cells resemble pig tissue, provoking an organ-rejection response.
www.nature.com
January 20, 2025 at 8:20 PM
Reposted by Anjali Gowripalan
Nearly three-quarters of biomedical researchers think there is a reproducibility crisis in science

https://go.nature.com/4joYKTT
‘Publish or perish’ culture blamed for reproducibility crisis
Survey of more than 1,600 biomedical researchers also flagged small sample sizes and cherry-picking of data as leading causes of reproducibility problems.
go.nature.com
January 20, 2025 at 10:58 AM
Reposted by Anjali Gowripalan
Implementation of intellectual property education in academic institutions can result in increased opportunities for protecting IP and limit costs, but to be successful technology transfer offices must also adapt go.nature.com/4iCtdhc
rdcu.be/d3sq8
January 8, 2025 at 9:09 PM
Reposted by Anjali Gowripalan
🎁 Early Xmas present from your friends at the MRC-University of Glasgow Centre for Virus Research @cvrinfo.bsky.social

We're thrilled to unwrap Viro3D - a comprehensive database of virus protein structures: >85,000 predicted structures from 4,400 human & animal viruses! 🦠

viro3d.cvr.gla.ac.uk
Viro3D
viro3d.cvr.gla.ac.uk
December 20, 2024 at 5:51 PM
Reposted by Anjali Gowripalan
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.

Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn
December 12, 2024 at 7:02 PM
🚨PUBLICATION ALERT!🚨
Shameless promotion of our new book chapter describing CASPRR, the friendly method for making recombinant poxviruses. Features a stable Cas9/gRNA cell line for further acceleration of previous protocols. Thanks Stewart Smith, @dctscharke.bsky.social

dx.doi.org/10.1007/978-...
Cas9-Mediated Poxvirus Recombinant Recovery (CASPRR) for Fast Recovery of Recombinant Vaccinia Viruses
Generation of recombinant vaccinia viruses opens many avenues for poxvirus research; however current methods for virus production can be laborious. Traditional methods rely on recombination strategies...
dx.doi.org
December 12, 2024 at 1:43 AM
Reposted by Anjali Gowripalan
First case of HPAI H7N6 in New Zealand poultry. First HPAI ever reported in NZ, unrelated to AUS H7 outbreaks
👉https://www.reuters.com/world/asia-pacific/new-zealand-reports-first-case-h7-bird-flu-2024-12-02/#:~:text=Tests%20showed%20a%20rural%20chicken,raised%20fears%20of%20human%20transmission
December 2, 2024 at 4:52 AM
So very grateful for the opportunity to present at #AVS12 among amazing company. Looking forward to the next one.
Next up is Anjali Gowripalan
Who is Using oncolytic viruses to save Tasmanian devils from transmissible facial tumours. A crushing disease for such a charismatic species. #AVS12
December 8, 2024 at 9:40 AM
Reposted by Anjali Gowripalan
AVS is now on bluesky - just in time for our biennial meeting starting today #AVS12
December 1, 2024 at 8:31 PM